Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report

Van den Bent MJ, Vogelbaum MA, Cloughesy T, Galldiks N, Albert NL, Tonn JC, Avila E, Fangusaro J, Mirsky D, Sahgal A, Soffietti R, Karschnia P, Mehta M, Kim MM, Boele F, Huse JT, Nayak L, Lim-Fat MJ, Le Rhun E, Desjardins A, Lee EQ, Chukwueke U, Koekkoek JA, Mendoza T, Loughan AR, Budhu JA, Bakas S, Huang RY, Villanueva-Meyer JE, Leone JP, Okada H, Reardon DA, Bi WL, Wen PY, Chang SM (2025)

Publication Type: Journal article, Review article

Publication year: 2025

Journal

Book Volume: 27

Pages Range: 2209-2224

Journal Issue: 9

DOI: 10.1093/neuonc/noaf118

Abstract

Since its first activities in 2008 and 2009, the Response Assessment in NeuroOncology (RANO) group has given guidance on response assessment, trial design, and trial procedures to improve and standardize the way clinical trials in neurooncological studies are performed. To achieve its objectives, a variety of working groups have been initiated that cover many aspects of clinical trial design and outcome assessment in patients with tumors affecting the Central Nervous System. The RANO working groups are built on expertise without a formal structure, which makes rapid responses to new developments possible. RANO is aiming at evidence-based guidelines and recommendations, but in the absence of evidence will provide consensus-based guidance achieved by inviting recognized international experts. In its 15 years of existence, more than 60 RANO papers have been published mostly in high-ranking journals, and its recommendations have been accepted by regulators and industry as guiding principles. RANO organizes two meetings per year, one in conjunction with the annual American Society for Clinical Oncology (ASCO) meeting, and one during the annual Society for Neuro-Oncology meeting. These meetings are open, as are the working groups of RANO. New initiatives are welcomed.

Involved external institutions

Erasmus University Medical Center (MC) Netherlands (NL) H. Lee Moffitt Cancer Center & Research Institute United States (USA) (US) University of California Los Angeles (UCLA) United States (USA) (US) Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf (CIO ABCD) Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Memorial Sloan Kettering Cancer Center United States (USA) (US) Emory University United States (USA) (US) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) University of Texas MD Anderson Cancer Center United States (USA) (US) Universitätsspital Zürich (USZ) Switzerland (CH) Harvard University United States (USA) (US) Leiden University Medical Center Netherlands (NL) National Cancer Institute (NCI) United States (USA) (US) Virginia Commonwealth University (VCU) United States (USA) (US) Indiana University Indianapolis (IUI) United States (USA) (US) University of California San Francisco (UCSF) United States (USA) (US) Klinikum der Universität München (LMU Klinikum) Germany (DE) University of Colorado Anschutz Medical Campus United States (USA) (US) Sunnybrook Health Sciences Centre Canada (CA) Florida International University United States (USA) (US) University of Michigan United States (USA) (US) University of Leeds United Kingdom (GB) Duke University Medical Center United States (USA) (US)

How to cite

APA:

Van den Bent, M.J., Vogelbaum, M.A., Cloughesy, T., Galldiks, N., Albert, N.L., Tonn, J.C.,... Chang, S.M. (2025). Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report. Neuro-Oncology, 27(9), 2209-2224. https://doi.org/10.1093/neuonc/noaf118

MLA:

Van den Bent, Martin J., et al. "Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report." Neuro-Oncology 27.9 (2025): 2209-2224.

BibTeX: Download